Concord Biotech lists with 21% premium on the BSE
Concord Biotech has debuted at Rs 900.05 on the BSE, up by 159.05 points or 21.46% from its issue price of Rs 741.
The scrip is currently trading at Rs 937.00, up by 196.00 points or 26.45% from its issue price. It has touched a high and low of Rs 987.05 and Rs 900.00 respectively. So far 12.88 lakh shares were traded on the counter.
The offering, which was open for subscription between August 4, 2023 and August 8, 2023 was subscribed 24.87 times. The issue price was fixed at Rs 741 per share i.e. at upper end of price band of Rs 705-741 apiece.
Concord is among the leading manufacturers of fermentation-based biopharmaceutical APIs, focused on niche segments, such as immunosuppressant, oncology, anti-fungal and anti-bacterial. It has three manufacturing facilities at Valthera, Dholka, and Limbasi, in Gujarat.
